Development of lipopolyplexes for gene delivery: a comparison of the effects of differing modes of targeting peptide display on the structure and transfection activities of lipopolyplexes by Bofinger, Robin et al.
Received: 27 April 2018 Revised: 6 September 2018 Accepted: 14 September 2018
DOI: 10.1002/psc.3131R E S E A R CH AR T I C L EDevelopment of lipopolyplexes for gene delivery: A
comparison of the effects of differing modes of targeting
peptide display on the structure and transfection activities of
lipopolyplexes
Robin Bofinger1 | May Zaw‐Thin2 | Nicholas J. Mitchell1† | P. Stephen Patrick2 |
Cassandra Stowe2 | Ana Gomez‐Ramirez2 | Helen C. Hailes1 | Tammy L. Kalber2 |
Alethea B. Tabor11Department of Chemistry, University College
London, 20, Gordon Street, London WC1H
0AJ, UK
2UCL Centre for Advanced Biomedical
Imaging, Division of Medicine, University
College London, London WC1E 6DD, UK
Correspondence
Alethea B. Tabor, Department of Chemistry,
University College London, 20, Gordon Street,
London WC1H 0AJ, UK.
Email: a.b.tabor@ucl.ac.uk
Tammy L. Kalber, UCL Centre for Advanced
Biomedical Imaging, Division of Medicine,
University College London, London WC1E
6DD, UK.
Email: t.kalber@ucl.ac.uk
Present Address
†School of Chemistry, University ofNottingham,
University Park, Nottingham NG7 2RD, UK
Funding information
Cancer Research UK, Grant/Award Numbers:
C1519/A6906 andC5255/A15935; Engineering
and Physical Sciences Research Council,
Grant/Award Number: EP/L006472/1; MRC,
Grant/Award Number: MR/K026739/1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of th
the original work is properly cited.
© 2018 European Peptide Society and John Wiley
J Pep Sci. 2018;e3131.
https://doi.org/10.1002/psc.3131The design, synthesis and formulation of non‐viral gene delivery vectors is an area of
renewed research interest. Amongst the most efficient non‐viral gene delivery sys-
tems are lipopolyplexes, in which cationic peptides are co‐formulated with plasmid
DNA and lipids. One advantage of lipopolyplex vectors is that they have the potential
to be targeted to specific cell types by attaching peptide targeting ligands on the
surface, thus increasing both the transfection efficiency and selectivity for disease tar-
gets such as cancer cells. In this paper, we have investigated two different modes of
displaying cell‐specific peptide targeting ligands at the surface of lipopolyplexes.
Lipopolyplexes formulated with bimodal peptides, with both receptor binding and
DNA condensing sequences, were compared with lipopolyplexes with the peptide
targeting ligand directly conjugated to one of the lipids. Three EGFR targeting peptide
sequences were studied, together with a range of lipid formulations and maleimide
lipid structures. The biophysical properties of the lipopolyplexes and their transfection
efficiencies in a basal‐like breast cancer cell line were investigated using plasmid DNA
bearing genes for the expression of firefly luciferase and green fluorescent protein.
Fluorescence quenching experiments were also used to probe the macromolecular
organisation of the peptide and pDNA components of the lipopolyplexes. We demon-
strated that both approaches to lipopolyplex targeting give reasonable transfection
efficiencies, and the transfection efficiency of each lipopolyplex formulation is highly
dependent on the sequence of the targeting peptide. To achieve maximum therapeu-
tic efficiency, different peptide targeting sequences and lipopolyplex architectures
should be investigated for each target cell type.
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2 of 12 BOFINGER ET AL.1 | INTRODUCTION
The delivery of oligonucleotide or genetic material to specific cells has
been a long‐term goal for treatment of intractable diseases such as
cancer, cystic fibrosis, retinal disorders, and cardiovascular disease. A
range of potential gene delivery systems, both viral and non‐viral, have
been used for the delivery of pDNA, siRNA, mRNA, and miRNA.1,2
Viral gene delivery systems have high efficiencies and generally show
good transfection properties in vitro and in vivo, with several in clinical
trials, and one (Glybera) recently approved in the EU.3 However, in
recent years, concerns about the potential safety of such approaches
have led to a renewed interest in non‐viral gene delivery vectors, as
these have lower immunogenicity, have the potential to deliver large
payloads, and can be functionalised to target specific cell types. A
range of nanoparticle‐based systems have been developed for gene
delivery,2 with the most common vectors being those based on
cationic lipids (lipoplexes), cationic polymers (polyplexes), or a combi-
nation of cationic lipids and cationic polymers (lipopolyplexes).1
Despite the advantages of non‐viral gene delivery vectors, in the
past they have been slow to progress to clinical use due to their gen-
erally lower efficiency of gene delivery. Recent understanding of the
barriers to efficient non‐viral vector delivery, such as nanoparticle
instability in vivo, poor targeting to specific cells, and inefficient
transport through biological barriers such as the cell membrane, has
led to an increased number of candidate vectors currently in clinical
trials.2 However, further improvements in these areas are still needed
to realise the potential of gene‐based therapies, in particular in the
treatment of cancers, where approaches such as suicide gene
therapy,4 regulation of gene expression by delivery of miRNA,5 p53
replacement gene therapy,6 and redirection of T‐cell specificity
towards cancer cells7 have recently shown promise. Targeting of
nanoparticles to tumors can be passive or active. Nanoparticles of
100 to 200 nm in diameter tend to accumulate in tumours, through
a combination of leaky tumor endothelium and ineffective lymphatic
drainage, a phenomenon known as the enhanced permeability and
retention effect (EPR).8 Whilst this passive targeting to tumors is
undoubtedly important, inter‐ and intra‐tumoral heterogeneity of
the tumor microenvironment means that the EPR effect may be more
pronounced in some tumors than others.9 Moreover, it is also clear
that accumulation in tumors is necessary, but accumulation on its
own is not sufficient for cellular uptake.10 This frequently needs to
be enhanced by the presence of cell‐specific targeting ligands on
the surface of the nanoparticles. Such targeting ligands both enhance
the selectivity of nanoparticles for cancer cells and may also trigger
internalisation via mechanisms such as receptor‐mediated endocyto-
sis. For example, exploiting the fact that epidermal growth factor
receptor (EGFR) is over‐expressed on the surface of many cancer cell
types, such as basal‐like breast cancer cells, has been very effective
in targeting nanoparticles to such tumors.11 A range of preclinical
studies have now demonstrated that active targeting improves the
efficacy of nanoparticle‐based therapies for several cancer types,12,13
and several targeted nanoparticle therapies are now in clinical trials.13
In addition, liposome‐based delivery systems and other nanoparticles
that are shielded from the reticuloendothelial system with a
surface coating of poly (ethyleneglycol) (PEG) or n‐ethylene glycol(n‐EG) have a significantly longer half‐life in vivo, allowing more of
the nanoparticles to localise to the tumor.14
Lipopolyplex gene delivery systems combine the desirable
features of lipoplexes and polyplexes with high in vivo transfection
efficiencies and a nanoscale size (100‐200 nm). They are self‐assem-
bling nanoparticles which can be formulated from a wide range of
components, enabling them to be tailored to many different applica-
tions and have multiple functionalities (reviewed in Rezaee et al15).
For example: formulation of LPD nanoparticles using cationic lipids
and peptide sequences derived from protamine or histone resulted
in enhancement of cell transfection in vitro16; in early work, RGD‐
targeted LPD revealed a 30‐fold increase in cell transfection com-
pared with the use of naked DNA17; lipopolyplexes incorporating a
fusion protein consisting of the carboxy‐terminal domain of histone
H1 and a nuclear localization signal gave transfection efficiencies
up to 20‐fold higher than lipofectin/DNA complexes.18 We have
previously developed targeted, environmentally responsive lipid:pep-
tide:DNA (LPD) lipopolyplexes for gene delivery. These lipopolyplex
formulations contain a bimodal peptide with a cationic sequence to
bind and condense pDNA,19 a linker sequence (RVRR) which can
be cleaved by enzymes within the endosome, and a targeting
sequence.20 The formulation of the lipopolyplexes also includes
cationic lipids such as DOTMA, and the helper lipid 1,2‐dioleoyl‐sn‐
glycero‐3‐phosphoethanolamine (DOPE). The latter is believed to
mediate release of the nanoparticle components from the endosome
by fusion to the endosomal membrane and perturbing the structure
to a non‐lamellar HII phase.
21 In the original paper describing the
LPD vector22 and in more recent work23 the order of mixing of
the lipid, peptide, and plasmid DNA were studied in detail, and it
was shown that this order of mixing was crucial to ensure high
transfection efficiencies. We have previously24 used a combination
of FCS, freeze‐fracture electron microscopy, and fluorescence
quenching experiments to prove the stoichiometry of the complex
and demonstrate that the DNA is tightly condensed to the peptide
in an inner core, which is surrounded by a disordered lipid layer,
from which the integrin‐targeting sequence of the peptide partially
protrudes, mediating internalization through receptor‐mediated
endocytosis. Indeed, it has been shown by several groups (most
recently Munye et al25) that cationic peptides more efficiently con-
dense and package DNA than cationic liposomes, a phenomenon
attributed to the higher charge density of the peptide molecules.26
We have recently developed lipopolyplexes which are sterically
shielded by a shallow but even coverage of n‐EG conferred by incor-
porating novel cationic lipids with short n‐EG at the headgroup
(n = 2‐6)20 and have studied the cellular uptake of the lipopolyplexes
and the intracellular distribution of the components by confocal
microscopy. We have also shown that liposomes formulated includ-
ing these n‐EG lipids form nanoparticles that are shielded with a
shallow, homogeneous n‐EG layer, and that these have much better
cellular uptake than liposomes formulated with 1,2‐distearoyl‐sn‐
glycero‐3‐phosphoethanolamine‐N‐[carboxy (polyethyleneglycol)2000]
(DSPE‐PEG2000).27 We have recently used this approach to formu-
late lipopolyplexes that selectively transfected tumor cells with
pDNA coding for a FRET biosensor and used this to monitor EGFR
inhibition by tyrosine kinase inhibitors in vivo using quantitative
BOFINGER ET AL. 3 of 12FRET‐FLIM imaging.28 In this work, the bifunctional peptide incorpo-
rated peptide sequences targeting EGFR, conferring tumor selectivity
and active targeting on these lipopolyplexes.
For these lipopolyplexes, the tumor selectivity and transfection
efficiency both depend on how well the targeting moiety is displayed
at the surface of the nanoparticle. A range of approaches for mounting
the targetingmoiety at the surface are possible29: as well as the bimodal
peptide approach that we have adopted in previous work, other groups
have successfully conjugated targeting peptides directly to the surface
of liposomes,30 lipoplexes,31 and polyplexes.32 However, it is impera-
tive to understand how subtle changes in the structures of the toolbox
components can affect both the macromolecular architecture of the
nanoparticles and also the selectivity, stability, and effective transfec-
tion in vivo of the resulting imaging probe.
In this paper, we have for the first time directly compared two dif-
ferent modes of attaching the targeting moiety to the lipopolyplex, via
the bimodal peptide approach versus direct conjugation to the lipid.
We have determined the effect that these two approaches have on
the macromolecular structure of the lipopolyplex and its transfection
efficiency. To develop this technology, we have used pDNA that has
optical readouts through the expression of either firefly luciferase33,34
or green fluorescent protein (GFP)35 with the aim that the lipopolyplex
formulations could then be applied to other targeted gene‐based
therapy approaches.2 | MATERIALS AND METHODS
2.1 | General methods, reagents, and chemical
synthesis
General methods for chemical synthesis are included in the Supporting
Information. All chemicals were of commercial quality and have
been used without additional purification. Unless otherwise stated
chemicals were bought from Sigma Aldrich Co. Ltd. 1,2‐Dioleoyl‐sn‐
glycero‐3‐phosphoethanolamine (DOPE) was purchased from Avanti
Polar Lipids Inc. 1,2‐Di‐O‐octadecenyl‐3‐trimethylammonium propane
(DOTMA) was synthesized according to literature procedures.36 2,3‐
Di‐((9Z)‐octadecenyloxy)propyl‐N‐(2‐{2‐[2‐(2‐hydroxyethoxy)ethoxy]
ethoxy}ethyl)‐N,N‐dimethylammonium bromide (DODEG‐4) wasTABLE 1 Molecular composition of lipids used for liposomal formulation
lipopolyplexes. Liposomes were made up to a total concentration of 1 mM
appropriate concentrations for the preparation of lipopolyplexes (100 μM
Formulation DODEG3 (Mol%) DOPE (Mol%) DOTM
Surface targeted F1 40 40 10
Surface targeted F2 40 35 10
Surface targeted F3 40 30 10
Surface targeted F4 40 30 20
Surface targeted F5 40 15 10
Surface targeted F6 30 25 10
Bimodal F7 40 40 20
Bimodal F8 40 20 20
Surface targeted F9 40 40 10synthesised as previously described.37 Experimental procedures for
the synthesis, purification, and characterisation of the novel maleimide
lipids DiOleyl‐Dimethyl‐Spacer‐Maleimide (DODSM) 1 and DiOleyl‐
Spacer‐EthyleneGlycol3‐Maleimide (DOSEG3M) 2 are described in
the Supporting Information. All peptides (Table S1) were synthesized
via solid‐phase peptide synthesis using Fmoc chemistry. The synthetic
procedures, purification methods, and compound characterisations are
reported in the Supporting Information.2.2 | Plasmid DNA
The lentiviral transfer vector plasmid pSEW38 was engineered for the
transient expression of firefly luciferase (5x FLuc)34 for biolumines-
cence, along with the enhanced GFP (eGFP) as a marker for fluores-
cence‐activated cell sorting (FACS) analysis.35 Plasmid DNA was
amplified in bacteria (One Shot Top10 competent cells, Invitrogen)
grown overnight in LB Broth with 100 μg/mL ampicillin, following
heat‐shock transfection with the plasmid DNA. DNA was extracted
and purified using a Qiagen PlasmidMaxi kit, according to themanufac-
turer's instructions, and eluted in de‐ionised water. DNA concentration
and purity were measured using a spectrophotometer (NanoDrop
2000, Thermofisher), and the DNA stock was stored at −20°C until use.2.3 | Lipopolyplex formulation
Bimodal peptide targeted lipopolyplexes: For lipopolyplexes bearing
their EGFR targeting peptide on the oligo‐lysine peptide, a mixture
of 40 mol% DODEG‐4, 20 mol% DOTMA, and 40 mol% DOPE (formu-
lation F7, Table 1) was prepared at a concentration of 1 mM in chloro-
form. The lipid mixture was slowly evaporated under reduced pressure
to form a lipid thin film and further dried under high vacuum for at
least 2 hours to ensure the complete removal of organic solvents.
The thin film was then hydrated with deionised water to give a lipo-
some solution with a final concentration of 1 mM lipids in water and
sonicated in a VWR ultrasonic bath (45 kHz, effective power 80 W)
to give an average size of around 200 nm. Subsequently, liposomes
were diluted to a concentration of 100 μM and a solution of the
corresponding bimodal peptide P1 (K16‐RVRR‐YHWYGYTPQNVI),
P2 (K16‐RVRR‐LARLLT), or P3 (K16‐RVRR‐AEYLR) was added to a
concentration of 5 μM, mixed and left standing for 5 minutes. Plasmids F1 to F9 for the preparation of surface targeted and bimodal
lipid and subsequently diluted with de‐ionised water to give the
unless otherwise noted)
A (Mol%) CHOL (Mol%) DODSM (1) (Mol%) DOSEG3M (2) (Mol%)
0 10 0
0 15 0
0 20 0
0 10 0
15 10 0
20 15 0
0 0 0
20 0 0
0 0 10
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liposome‐peptide mixture to give bimodal peptide targeted
lipopolyplexes.
Surface‐targeted lipopolyplexes: For liposomes bearing the EGFR
targeting peptide sequence on the lipid component, mixtures of
DODEG‐4, DOTMA, DODSM 1 or DODEG3SM 2 and DOPE were
prepared in the ratios shown in Table 1, at a concentration of 1 mM
in chloroform. The lipid mixture was slowly evaporated under reduced
pressure to form a lipid thin film and further dried under high vacuum
for at least 2 hours to ensure complete removal of organic solvents.
The thin film was then hydrated with deionised water to give liposome
solutions F1 to F6 and F9 (Table 1) with a final concentration of 1 mM
lipids in water. These liposome solutions were then sonicated in a
VWR ultrasonic bath (45 kHz, effective power 80 W) to give lipo-
somes with an average size of approximately 200 nm. Peptide
targeting sequences P4 (CYHWYGYTPQNVI), P5 (CLARLLT), and P6
(CAEYLR), all with Cys residues at the N‐terminus, were then added
to a final concentration of 1 mM and incubated for 2 hours. The
liposomes were diluted to a lipid concentration of 500 μM and
dialysed against deionised water (BioDesignDialysis Tubing (D001),
14000 MWCO) over 16 hours during which the water was changed
3 times. Subsequently, the peptide‐covered liposomes were diluted
to a concentration of 100 μM, and a solution of oligo‐lysine (K16,
P7) was added to a concentration of 5 μM, mixed and left standing for
5 minutes. Plasmid DNA was added to a concentration of 1 μg/100 μL
DNA per liposome peptide mixture to give lipid bound targeted
lipopolyplexes.
The final composition of all lipid formulations used for the prepa-
ration of both surface targeted and bimodal liposomes is summarised
in Table 1.
2.4 | Dynamic light scattering and zeta potential
The lipopolyplexes were characterised using dynamic light scattering
and zeta potential measurements. Data were obtained using a Malvern
Zetasizer Nano‐ZS (Malvern, UK). Aliquots of 10 μL were diluted to
500 μL in deionised water and analysed in triplicates. A representative
sample of the prepared liposomal formulations and the resulting
lipopolyplexes are reported in the Supporting Information (Tables S2,
S3, and S4).
2.5 | Cell culture
HCC1954 human breast cancer cells were grown inT175 flasks (Fisher
Scientific, UK) in Roswell Park Memorial Institute (RPMI‐1640)
medium (Invitrogen, UK), supplemented with 10% heat inactivated
fetal calf serum (GIBCO, USA) in a humidified incubator at 37°C with
95% air and 5% CO2. Cells were grown to 80% confluence prior to
trypsinisation, counting, and plating for in vitro experiments.
2.6 | Liposome‐mediated transfection
HCC1954 cells were plated in six‐well plates (Corning, USA) at a con-
centration of 5 × 105 cells per well in triplicate and incubated over-
night to 80% confluency. Prior to adding liposomes, normal culture
medium was aspirated from the wells, and the cells were washed oncewith phosphate buffered saline (GIBCO, USA), and 2 mL of serum free
RPMI‐1640 was added. Then, 100 μL of either liposomes or phos-
phate buffered saline (control) was added to each well and incubated
at 37°C. After 4 hours, 2 mL of normal culture medium was added
and the mixture incubated for an additional 20 hours. After 24 hours,
the incubation medium was aspirated from the wells and 2 mL of nor-
mal RPMI 1640 was added. At 24 and 48 hours after incubation, an
in vitro bioluminescence assay (firefly luciferase expression) and FACS
(eGFP expression) were performed as a read out of liposome mediated
transfection efficiency.
Cell sorting was performed using a BD LSRFortessa (Becton
Dickinson, USA) to assess the percentage of eGFP expression in each
well. FACS analysis was performed using BD FACSDiva software
(version 8.0.1).
The in vitro bioluminescence assay was performed using a IVIS
Lumina (PerkinElmer, USA), and images were acquired immediately
after adding D‐luciferin (300 μg/mL, beetle luciferin potassium salt,
Promega, Madison, WI) using large binning and exposure time of
300 seconds. A region of interest was placed over each well, and the
total radiance (photons/s) was quantified using Living Image software
(version 4.5.2).
A two‐tailed paired t‐test assuming equal variances was per-
formed to determine significant difference, at the 5% level statistical
significance. Errors are given as standard deviation.
2.7 | Fluorescence quenching
Fluorescence quenching experiments were carried out on an Agilent
Cary Eclipse fluorometer equipped with a single water thermo cell
holder. Spectral grade solvents were used for the fluorescence
measurements. The preparation of fluorescein‐labelled pDNA and
BODIPY‐labelled peptides P8 and P9 is described in the Supporting
Information. Lipopolyplexes for fluorescence measurements were pre-
pared at 200‐μM lipid, 0.02 μg/μL plasmid DNA, and 10 mM peptide.
The lipopolyplex samples were diluted to a lipid concentration of
30 μM, and a total volume of 1.4 mL before fluorescence spectra were
recorded and acrylamide was added.24 Collisional quenching of the
fluorescence was plotted using the Stern‐Volmer equation:
F0
F
¼ kQ τ0 Q½ 
where F0 and F are the fluorescence intensities in the absence and
presence of quencher Q, respectively, kQ is the bimolecular quenching
constant, and τ0 is the lifetime of the fluorophore in the absence of
quencher. For species in which a single population of fluorophores is
present, all equally accessible to the quenching agent, a plot of F0/F
will give a linear graph.393 | RESULTS AND DISCUSSION
3.1 | Design of lipopolyplexes: peptide targeting and
lipopolyplex architecture
In order to exploit the overexpression of the EGF receptor at the sur-
face of the basal‐like breast cancer cells used in this study, three
BOFINGER ET AL. 5 of 12peptides were investigated that have recently been reported to target
this receptor. The GE11 (YHWYGYTPQNVI),40 D4 (LARLLT),41 and AE
(AEYLR)42 peptide sequences were previously identified as suitable
ligands, via phage display or in silico peptide library screening. These
sequences have been successfully used to target liposomes30,41 and
polyplexes42 to tumor cells. As previous studies have shown that the
transfection efficiency and route of cellular uptake of such targeted
nanoparticles were highly dependent on cell type,43 we elected to
compare all three of these sequences in the lipopolyplex formulations.
The lipopolyplex formulation utilised was based on a single, multi-
functional peptide which will both condense pDNA and target the
nanoparticle to cell surface receptors. We have previously shown that
this necessitates the targeting peptide protruding through the surface
of the lipid layer, resulting in the “bifunctional peptide” design shown
in Figure 1.24 For these lipopolyplex formulations, peptides P1, P2,
and P3 were synthesised, with K16 condensing sequences, the RVRR
enzymatically cleavable linker, and the GE11 (P1), D4 (P2), or AE
(P3) sequences. However, it was reasoned that the targeting sequence
might be more sterically accessible to the receptor if it was conjugated
to the surface of the nanoparticle, with a separate K16 peptide (P7)
included in the formulation to condense the pDNA, giving the “surface
targeted” design (Figure 1).
Bioconjugation of targeting moieties to lipids or to liposomes is
typically carried out via the reaction of thiol‐functionalised targeting
moieties to malemide‐derivatised lipids, using click chemistry, or amide
bond formation,29,44 although hydrazone linkages45 and Staudiger
ligations44 have also been reported. The majority of peptide‐targeted
liposomes to date have relied on the post‐formulation bioconjugationFIGURE 1 Schematic representation of (top) bimodal peptide targeted lip
targeting sequence, a furin cleavable RVRR linker, a DNA condensing K16 se
an EGFR targeting sequence bioconjugated to the lipid bilayer, and a separ
DNA components used in these experiments are shown on the right handof thiol‐functionalised targeting moieties to liposomes containing
DSPE‐PEG2000‐Mal,29,30,41 although other maleimide‐containing
lipids with shorter or no PEG linkages have been reported.31,46,47
For the surface targeted lipopolyplexes two lipids with maleimide moi-
eties at their head group were synthesised, for incorporation into the
liposome formulations and then conjugation to peptide targeting
sequences terminating in Cys residues. DODSM (DiOleyl‐Dimethyl‐
Spacer‐Maleimide) 1 was designed to be a cationic lipid analogue
of DOTMA, whilst DOSEG3M (DiOleyl‐Spacer‐EthyleneGlycol3‐
Malelimide) 2 is a neutral lipid with a short n‐EG spacer between the
lipid headgroup and the maleimide moiety.
DODSM (1), with the cationic headgroup, was designed to evalu-
ate whether the relative location of the malemide on the surface of
the liposomal formulation would have an impact on transfection effi-
ciency or lipopolyplex architecture. Due to the positive charge of the
headgroup, the maleimide moiety might be in closer proximity with
the aqueous exterior of the lipopolyplex. The synthesis for both
maleimide bearing lipids is shown in Scheme 1. Amine 3 was prepared
according to literature procedures37 and reacted with N‐maleoyl‐ß‐
alanine (4) using HBTU and DIPEA to give DODSM 1. Amine 5 was
prepared as previously described27 and similarly reacted with 4 to
yield the desired maleimide lipid DOSEG3M 2.3.2 | Formulation of targeted lipopolyplexes
The bimodal peptide targeted lipopolyplexes were formulated using
our previously published procedures.24 A mixture of lipids was first
used to produce liposomes and give formulations F7 or F8 (Table 1).opolyplexes formulated with a bimodal peptide consisting of an EGFR
quence, and (bottom) surface targeted lipopolyplexes formulated using
ate K16 peptide to condense the DNA. The lipid, peptide, and plasmid
side
SCHEME 1 Synthesis of DiOleyl‐dimethyl‐
spacer‐Maleimide (DODSM, 1) and DiOleyl‐
spacer‐EthyleneGlycol‐3‐Maleimide
(DOSEG3M, 2)
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followed by luciferase plasmid DNA, giving the desired bimodal
targeted lipopolyplexes (Table S2).
Surface targeted lipopolyplexes for this study were prepared in a
similar manner (Scheme 2). Liposomal formulations with either the
charged lipid (1) (formulations F1, F2, F3, F4, F5, F6) or the neutral
lipid (2) (formulation F9) incorporated into the lipid bilayer were pre-
pared and subsequently incubated with Cys bearing targeting peptides
P4, P5, or P6 to give targeted liposomes. The excess unbound
targeting peptide was then removed via dialysis and the liposomal for-
mulation incubated with a DNA‐condensing peptide K16 (P7) followed
by plasmid DNA to form the final surface targeted lipopolyplexes
(Table S2). A schematic representation of the formation process is
depicted in Scheme 2.
For both types of lipopolyplex, the initial liposome solution was
sonicated to obtain an average particle size below 500 nm with a zeta
potential of between +23 and +43 mV (Table S3). The liposomal for-
mulation for bimodal targeted lipopolyplexes exhibited slightly higher
surface charges than the surface targeted formulation despite using
only 5 mol% more charged lipids in the bimodal formulation. The zeta
potential difference is probably due to the shielding effect of the
maleimide bearing lipids, analogous to the manner in which large
PEG groups shield the charge of cationic lipoplexes.48 After the addi-
tion of the K16 containing peptides (P1‐P3, P7) and plasmid DNA,
the average size of the samples slightly increased while the zeta
potential slightly decreased to values ranging from +15 to +33 mV
(Table S4) indicating the formation of stable lipopolyplexes with the
negatively charged plasmid DNA reducing partially the overall positive
charge. While it is known that lipoplexes of up to 250 nm are almost
exclusively endocytosed by clathrin coated pits of non‐phagocyticSCHEME 2 Schematic showing the preparation of surface targeted lipopB16 cells, particles of sizes around 500 nm are internalised via
caveolae.49 No studies on the contribution of particle size on the
internalisation pathway of lipopolyplexes has been conducted so far,
but it can be assumed that the broad size distribution of the presented
lipopolyplex with an average size above 250 nm may trigger different
endocytosis mechanisms. However, a major contribution of receptor‐
mediated endocytosis was expected due to the presence of EGFR
targeting peptides.203.3 | Transfection of HCC1954 human breast cancer
cell line
We initially investigated the surface targeted lipopolyplexes, which
were optimised by changing different parameters such as the lipid
composition or the ratio between peptide and DNA. The relative
merits of using either maleimide lipid 1 or 2 to conjugate the targeting
peptides (P4‐P6) to the exterior of the liposome were first examined.
As described above, formulation F1 (with DODSM 1) or formulation
F9 (with DODEG3SM 2), respectively, were conjugated to P4 to P6,
followed by formulation into lipopolyplexes by the addition of
5 μM K16 peptide (P7) and then 0.01 μg/μL pDNA. As a control, for-
mulation F7 was complexed with peptide P7 and pDNA to give the
non‐targeted lipopolyplex F7‐(P7)‐REF (Table S2). The transfection
efficiency of the plasmid DNA into HCC1954 cells was assessed via
bioluminescent light emission in radiance (firefly luciferase expression)
and FACS analysis (eGFP expression) after 24 and 48 hours, respec-
tively (Figure 2A). When DODSM 1 was used as the maleimide bear-
ing component (lipopolyplexes F1‐(P4,P7), F1‐(P5,P7), and F1‐(P6,
P7)) the bioluminescence output was similar to the control
non‐targeted lipopolyplex F7‐(P7)‐REF at 24 hours but exhibited aolyplexes
FIGURE 2 Optimisation of lipid formulations for the surface targeted lipopolyplexes. A, Total luciferase emission of HCC1954 cells transfected
with lipopolyplexes prepared from lipid formulations F1 (DODSM), F9 (DOSEG3M), and F7 (no maleimide‐lipid) covalently linked to EGFR
targeting peptides (P4‐P6) via maleimide‐thiol crosslinking and complexed with K16 (P7) and luciferase pDNA. B, Total luciferase emission of
HCC1954 cells transfected with lipopolyplexes prepared from liposomal formulations F1‐F7 containing DODSM, covalently linked to EGFR
targeting peptide P5 and complexed with P7 and luciferase pDNA. Error bars are standard deviation (n = 3)
BOFINGER ET AL. 7 of 12distinctive increase (1.5‐1.8 fold) at 48 hours. This indicated good
accessibility to the targeting functionalities and enhanced transcrip-
tion of the plasmid DNA (Figure 2A) in the presence of 1. Conversely,
all lipopolyplexes containing DOSEG3M 2 (F9‐(P4,P7), F9‐(P5,P7), and
F9‐(P6,P7)) showed significantly lower bioluminescence compared
with the non‐targeted reference at both the 24 hours (P ≤ 0.05) and
48 hours (P ≤ 0.001) time point. One possible explanation for this is
that the more polar maleimide headgroup‐linker moiety in DODSM
protrudes further out from the bilayer, whereas the less polar
headgroup‐linker moiety in DOSEG3M could interact with the
hydrophobic part of the liposome bilayers.50
Lipopolyplexes containing DODSM 1 were therefore selected for
further study. As lipopolyplexes bearing the EGFR targeting LARLLT
peptide P5 at the surface appeared from these preliminary studies to
have slightly superior transfection efficiencies, we used this peptide
sequence in studies to further optimise the composition of the lipid
bilayer (Figure 2B). The ratios of DODSM, DOPE, and DOTMA were
varied as shown in Table 1 (liposome formulations F1, F2, F3, F4),
and lipopolyplexes containing cholesterol (liposome formulations F5,
F6) were also investigated. All of the resulting lipopolyplexes showed
significantly increased bioluminescence (P ≤ 0.001) for both 24 and
48‐hour time points compared with the non‐targeted reference
lipopolyplex F7‐(P7)‐REF. This suggests that altering the lipid compo-
sition did not significantly affect targeted transfection efficiency. Lipo-
somes containing 1 in the lipid bilayer in the range of 10 to 15 mol%
(F1‐(P5,P7), F2‐(P5,P7)), had the highest bioluminescence (48 hours).
Whereas, increasing the percentage further to 20 mol% (F3‐(P5,P7))
appeared to hinder transfection resulting in a reduction in biolumines-
cence at 48 hours. Increasing the overall charge of the complex (F4‐
(P5,P7)) by increasing the percentage of DOTMA resulted in a more
rapid transfection efficiency, with the highest bioluminescence at
24 hours. However, this did not increase to the extent of other
lipopolyplexes at 48 hours. Finally, adding cholesterol to the
formulation (F5‐(P5,P7), (F6‐(P5,P7)) also significantly reduced biolu-
minescence at both time points when compared with F1‐(P5,P7) and
F2‐(P5,P7) (P ≤ 0.05), suggesting that cholesterol may affect the
transfection efficiency, perhaps by increasing the rigidity of the
bilayer. In order to maximise the number of sites for conjugation ofthe targeting peptide to the surface, it was decided to carry out
further optimisation of the peptide targeting sequence based on the
F2‐(P5,P7) formulation.
Turning to the bimodal peptide targeted lipopolyplexes,
peptides (P1, P2, and P3) were designed to have a pDNA binding
sequence (K16) and a validated EGFR‐binding sequence (GE11
(YHWYGYTPQNVI),40 D4 (LARLLT),41 and AE (AEYLR)42) connected
together by a furin‐cleavable linker sequence (RVRR), following our
earlier work on the design of bimodal peptide targeted
lipopolyplexes.19,20,24 Initially, the ratio between plasmid DNA and
peptide was varied to find the optimized ratio that produces the
highest bioluminescence emittance suggestive of the greatest lucifer-
ase expression (Figure 3A‐D). While keeping plasmid DNA concentra-
tion at 0.01 μg/μL, bimodal peptides were varied between 2.5 and
20 μM. As a control, the non‐targeted lipopolyplex formulation F7‐
(P7)‐REF with a bimodal peptide concentration of 5 μM was used. A
concentration of 5‐μM bimodal peptide was found to give the highest
bioluminescence reading at both 24 and 48 hours for targeting pep-
tides LARLLT (F7‐(P2)) and AEYLR (F7‐(P3)) compared with the con-
trol (F7‐(P7)‐REF) (P ≤ 0.05), whereas the longer GE11 (F7‐(P1))
targeting sequence showed only a slight enhancement of biolumines-
cence. Adding cholesterol to the lipopolyplex formulation at a concen-
tration of 5 μM bimodal peptide (F8‐(P1), F8‐(P2), F8‐(P3)) or altering
the concentration of bimodal peptide (P1‐P3) to either 2.5 or 10 μM
had little effect on transfection efficiency, exhibiting similar levels of
bioluminescence to the control (F7‐(P7)‐REF). However, increasing
P1 to P3 to 20 μM appeared to significantly reduce gene expression
levels compared with the non‐targeted reference at 48 hours
(P ≤ 0.001).
Having optimised the formulations for transfections using bimodal
peptide targeted lipopolyplexes, we chose F7 with the biomodal pep-
tide concentration at 5 μM for the optimised bimodal peptide targeted
lipopolyplex (Figure 3) and the F2 formulation as the optimised surface
targeted lipopolyplex (Figure 2). We then compared the two
lipopolyplex targeting methods directly, using all three of the EGFR
receptor targeting sequences (P1‐P3 for the bimodal peptide and
(P4, P7)‐(P6, P7) for the surface targeted). Again, these were com-
pared with the control non‐targeted lipopolyplex P7‐(P7)‐REF.
FIGURE 3 Optimisation of lipid formulations for the bimodal peptide targeted lipopolyplexes. (A‐D) Total luciferase emission of HCC1954 cells
transfected with lipopolyplexes prepared from lipid formulation F7 and F8 (5 μM only—B) complexed with bimodal peptides (P1, P2, P3, and P7‐
REF) at concentrations 2.5 μM (A), 5 (B), 10 μM (C), and 20 μM (D) and luciferase pDNA
8 of 12 BOFINGER ET AL.Bioluminescence was recorded as in previous experiments (Figure 4A)
and compared with the expression of eGFP (Figure 4B) that was
encoded on the same plasmid. FACS counting of eGFP expression
was used to quantify the total percentage of transfected cells in a pop-
ulation. Bioluminescence was used to give a readout of transfection
efficiency as the more luciferase produced results in a higher photon
count when the same amount of luciferin is added. The percentage
population of cells expressing eGFP was similar or higher for both
the bimodal and surface targeted liposomes when compared with
the non‐targeted reference F7‐(P7)‐REF. This suggests that the num-
ber of cells being transfected is similar if not better than the control.
However, the LARLLT and AEYLR targeting sequences for both theFIGURE 4 Comparison of luciferase emission in (A) HCC1954 cells and
optimised formulations of bimodal peptide targeted (F7‐(P1), F7‐(P2), F7‐(
lipopolyplex formulationsbimodal peptide targeted lipopolyplexes (F7‐(P2) and F7‐(P3)) and sur-
face targeted lipopolyplexes (F2‐(P5, P7) and F2‐(P6, P7)) had biolumi-
nescence emission far higher than that of the non‐targeted reference
F7‐(P7)‐REF at both 24 and 48 hours (P ≤ 0.01). As the percentage
population by eGFP shows similar results to the non‐targeted refer-
ence, this suggests that the cells being transfected have a higher trans-
fection efficiency which is most likely due to enhanced transcription of
the luciferase gene. For the longer GE11 sequence, although the
bimodal (F7‐(P1)) lipopolyplex had a higher bioluminescence photon
count than the surface targeted (F2‐(P4,P7)) lipopolyplex, their expres-
sion was similar if not slightly lower (F2‐(P4,P7)) than the control (F7‐
(P7)‐REF). We therefore undertook a structural investigation of the(B) HCC1954 cells expressing GFP (right) after incubation with the
P3)) and surface targeted (F2‐(P4,P7), F2‐(P5,P7), F2‐(P6,P7))
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lipopolyplexes, in order to understand the observed differences in
transfection efficiencies.3.4 | Characterisation of the macromolecular
structure of the lipopolyplexes
In order to understand the differences in transfection efficiencies
displayed by the bimodal and surface targeted lipopolyplexes, we con-
ducted fluorescence quenching experiments to elucidate the location
of the different components within the lipopolyplex.24 In order to
study the accessibility and location of the targeting sequence itself,
we used the GE11 (YHWYGYTPQNVI) sequence, as the intrinsic fluo-
rescence of the Trp residue in this sequence made additional
fluorophore labelling unnecessary. Thus, formulations F7‐(P1)
(bimodal) and F2‐(P4,P7) (surface targeted) were made up at higher
concentrations, and then increasing concentrations of acrylamide
were added as a quencher.39 As a control, the quenching of the free
peptide P1 was taken to provide an indication of the quenching
behaviour of a completely accessible peptide (Figure 5A). Further-
more, to provide a measure for a completely shielded fluorophore,
5(6)‐carboxyfluorescein was encapsulated into DPPC liposomes and
subjected to the same quenching conditions used for the
lipopolyplexes (Figure S1). Quenching efficiencies for the Trp residue
in the surface targeted lipopolyplex F2‐(P4,P7) were slightly lowerFIGURE 5 A, Stern‐Volmer plot for the quenching of bimodal lipopol
targeted liposome F2(P4). The overall lipid concentration = 200 μM, pepti
targeting sequence (YHWYGYTPQNVI) was present in all peptides, and th
addition of acrylamide (0‐50 mM). B, Stern‐Volmer plot for the quenching o
a final concentration of 2‐μM F4‐BODIPY bearing peptide P8, bimodal lip
BODIPY bearing peptide P9 (overall lipid concentration = 200 μM, peptide
0.02 μg/μL). The BODIPY emission at λem = 530 nm (λexc = 557 nm) wasthan the quenching efficiency obtained from the free peptide P1. This
may indicate that when the targeting peptide is mounted on the lipo-
somal surface, it is sufficiently close to the lipid bilayer to limit the
rotational freedom of the peptide and restrict access of the acrylamide
quencher to the fluorophore. However, the bimodal formulation F7‐
(P1) showed quenching efficiencies similar to the free peptide P1, indi-
cating that in these lipopolyplexes the targeting part of the bimodal
peptide protrudes through the lipid bilayer and is fully accessible to
the acrylamide, as we have observed previously.24
In order to study the location of the DNA‐binding sequences in
both the surface targeted and bimodal lipopolyplexes, we designed
and synthesised two further peptides labelled with a fluorophore
attached at the N‐terminal end of the DNA‐binding K16 sequence.
Thus, the sequence CK16 was site‐selectively labelled with a
fluorophore as follows. A perfluoro‐BODIPY51 functionalised in the
para‐position of the perfluorophenyl ring was reacted via a nucleo-
philic aromatic substitution52 to give maleimido‐F4‐BODIPY. This
was then conjugated to CK16 to give peptide P8 (F4‐BODIPY‐CK16).
Likewise, the peptide CK16‐RVRR‐YHWYGYTPQNVI was synthesised
and site‐selectively conjugated to maleimido‐F4‐BODIPY via
the Cys residue to give peptide P9 (F4‐BODIPY‐CK16‐RVRR‐
YHWYGYTPQNVI) (Figure 5). The bimodal lipopolyplex F7‐(P1) was
then formulated incorporating a final concentration of 2 μM F4‐
BODIPY bearing peptide P9, and the surface targeted lipopolyplex
F2‐(P4,P7) was formulated incorporating a final concentration of
2 μM F4‐BODIPY bearing peptide P8. Similar quenching experimentsyplex F7‐(P1), surface targeted lipopolyplex F2‐(P4,P7), and surface
de = 10 μM, luciferase plasmid DNA 0.02 μg/μL). The GE11 EGFR
e Trp emission at λem = 340 nm (λexc = 280 nm) was quenched upon
f F4‐BODIPY in surface targeted lipopolyplex F2‐(P4,P7) incorporating
opolyplex F7‐(P1) incorporating a final concentration of 2‐μM F4‐
= 10 μM, F4‐BODIPY peptides = 2 μM, luciferase plasmid DNA
quenched upon addition of acrylamide (0–50 mM)
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labelled peptide is completely internalised in the bimodal lipopolyplex
formulation F7‐(P1,P9) (Figure 5B) with the fluorophore protected
from the acrylamide quencher. In the surface targeted lipopolyplex
F2‐(P4,P7,P8), good shielding from the quencher was equally
observed, indicating internalisation of the BODIPY‐K16/DNA complex.
Both linear Stern‐Volmer slopes resemble the one of completely
encapsulated fluorescein (Figure S1).
In order to verify the location of the pDNA in the two
lipopolyplexes, the luciferase plasmid DNA was labelled using a
functionalised fluorescein (Supporting Information). However, no
quenching of the lowest energy fluorescence emission band was
recorded upon the addition of acrylamide (Supporting Information,
Figure S2) for either the free labelled pDNA or the lipopolyplex encap-
sulated pDNA, indicating a shielding effect of the fluorophore by the
more hydrophilic DNA. It is important to note that the overall emission
of the labelled pDNA was generally low, resembling the spectra of a
self‐quenched fluorophore, but after incorporation into a liposomal
environment the typical fluorescence emission spectra of fluorescein
recovered with a more then 4‐fold increase in emission intensity.
Self‐quenching of fluorophores in macromolecules such as DNA is a
known issue due to labelling of neighbouring sites supported via
hydrophobic self‐assembly of the dye molecules.53 Despite that initial
self‐quenching, it should be noted that once incorporated into the
lipopolyplex the fluorescein labeled pDNA remains shielded from the
quenching agent in the bulk water. The change in shape of the emis-
sion spectra can be attributed to the more hydrophobic environment
of the lipopolyplex and the formation of a ternary complex
with the cationic peptide which increases the distance between
neighboring fluorophores.4 | CONCLUSIONS
Due to their demonstrated bio‐safety, reduced pathogenicity, low cost,
and ease of production, lipopolyplexes remain a viable alternative to viral
vectors for gene delivery applications. The addition of cell‐specific
targeting ligands on the surface of liposome‐based nanoparticles
enhances the cellular uptake and transfection efficiency. For
instance, in a comparative study54 of the transfection efficiencies of
lipopolyplexes formulated from bimodal peptides with and without
targeting, lipopolyplexes with a scrambled targeting sequence showed
25% transfection, and lipopolyplexes with the targeting sequence
removed showed 12% transfection, compared with lipopolyplexes with
targeting sequence, indicating that the high transfection efficiency is at
least partly a consequence of the targeting sequence. In another study,41
surface targeted liposomes bearing the GE sequence were compared
with surface targeted liposomes with the sequence scrambled; the
scrambled sequences had negligible binding to cells in vitro. However,
a systematic investigation of the benefits of different methods of
displaying the targeting peptide had not previously been reported.
In this study, we have for the first time compared two approaches
to the design, synthesis, and formulation of cell‐surface receptor
targeted lipopolyplexes for gene delivery. Surface‐targeted
lipopolyplexes were prepared from liposomes to which targetingpeptides had been attached, and bimodal peptides were formulated
directly, using peptides which contained both DNA condensing and
receptor targeting sequences. Three targeting sequences, previously
validated to target the EGF receptor which is over‐expressed in many
cancer cell lines, were investigated, together with a range of lipid for-
mulations and maleimide lipid structures. The biophysical properties of
the lipopolyplexes and their transfection efficiencies in a basal‐like
breast cancer cell line were investigated, and fluorescence quenching
experiments were used to probe the macromolecular organisation of
the peptide and pDNA components of the lipopolyplexes.
Both approaches to lipopolyplex targeting gave reasonable trans-
fection efficiencies, with little major differences between them. This
reflects the observations from the fluorescence quenching experi-
ments that in both types of liposomes the pDNA is condensed and
shielded within the lipopolyplex, and also that in both cases the
targeting moiety is accessible to some degree. Moreover, it is clear
that the transfection efficiency of each lipopolyplex architecture is
highly dependent on the sequence of the targeting peptide. The
GE11 (YHWYGYTPQNVI) sequence gave the lowest transfection effi-
ciency when incorporated in the surface targeted liposomes. In the
fluorescence quenching experiments, the Trp residue of this sequence
is partially shielded, suggesting that in this case the targeting sequence
is partly shielded and thus is less accessible. However, the D4
(LARLLT) targeting sequence outperformed other surface targeted
and bimodal lipopolyplexes, suggesting that this sequence has optimal
accessibility to cell surface receptors.
In this work, we have demonstrated the versatility of differing
approaches to functionalizing lipopolyplexes for targeted gene
delivery which provides a toolbox for a more personalised targeting/
treatment to specific cancer cell lines. Our findings indicate that there
is little difference in transfection efficiency and targeting sequence
display between the two approaches. Lipopolyplex targeting to cancer
cell lines is clearly highly dependent on the targeting sequence used,
and that selection and optimisation of both targeting sequence and
lipopolyplex architecture should be carried out on a case‐by‐case
basis, taking into account the cancer cell line of interest, the receptor
binding of the targeting sequence, and the slightly greater synthetic
complexity of the surface targeting approach.ACKNOWLEDGEMENTS
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